This case details the clinical experience of a biomarker-negative patient with recurrent metastatic cervical adenocarcinoma who, following curative surgery, received 2 lines of chemotherapy and radiation of metastases, has seen a long-term response to the PD-1 blockade Zimberelimab, the best tumor response was PR (RECIST1.1) and no noticeable adverse reactions were observed. Here, PDCD1 is linked to neoplasm.